Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy

Urology

Volumn 49, Issue 3 SUPPL., 1997, Pages 16-22

  Reuter, Victor E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; CANCER HORMONE THERAPY; CANCER REGRESSION; CELL ULTRASTRUCTURE; CONFERENCE PAPER; DRUG EFFECT; HISTOPATHOLOGY; HORMONE INHIBITION; HUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; TUMOR VOLUME;

EID: 0030890120     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00164-7     Document Type: Conference Paper

References (31)

1. Epstein JI, Pizov G, and Walsh PC: Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71: 3582-3593, 1993.
2. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Eng J Med 321: 419-424, 1989. (Erratum appears in N Eng J Med 321: 1420, 1989).
3. Labrie F, Dupont A, and Belanger A: Complete androgen blockade for the treatment of prostate cancer, in DeVita VT Jr, Hellman S, Rosenburg SA (Eds): Important Advances in Oncology. Philadelphia, JB Lippincott, 193-217, 1985.
4. Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, Laberge JG, Emond JP, Fazekas AT, and Raynaud JP, et al: New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5: 267-275, 1982.
5. Labrie F, Dupont A, Cusan L, Giguere M, Bergeron N, Borsanyi JP, Lacourciere Y, Belanger A, Emond J, and Monfette G et al: Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice. J Steroid Biochem 30: 107-117, 1988.
6. Johnson DE, Scott WW, Gibbons RP, Prout GR, Schmidt JD, Chu TM, Gaeta J, Saroff J, and Murphy GP: National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: progress report. Cancer Treat Rep 61: 317-323, 1977.
7. Jordan WP Jr, Blackard CE, and Byar DP: Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. South Med J 70: 1411-1413, 1977.
8. Mettlin C, Natarajan N, and Murphy GP: Recent patterns of care of prostatic cancer patients in the United States: results from the surveys of the American College of Surgeons Commission on Cancer. Int Adv Surg Oncol 5: 277-321, 1982.
9. Murphy GP, Beckley S, Brady MF, Chu TM, de Kernion JB, Dhabuwala C, Gaeta JF, Gibbons RP, Loening SA, and McKiel CF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51: 1264-1272, 1983.
10. Nesbit RM, and Baum WC: Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. J Am Med Assoc 143: 1317-1320, 1950.
11. Resnick MI, and Grayhack JT: Treatment of stage IV carcinoma of the prostate. Urol Clin North Am 2: 141-161, 1975.
12. St. Arnaud R, Lachance R, Dupont A, and Labrie F: Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen. J Clin Endocrinol Metab 63: 297-302, 1986.
13. Belanger A, Dupont A, and Labrie F: Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic carcinoma. J Clin Endocrinol Metab 59: 422-426, 1984.
14. Drago JR, Santen RJ, Lipton A, Worgul TJ, Harvey HA, Boucher A, Manni A, and Rohner TJ: Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer 53: 1447-1450, 1984.
15. Neri R, Florance K, Koziol P, and Van Cleave S: A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4′-nitro 3′trifluoromethylisobutyranilide). Endocrinology 91: 427-437, 1972.
16. Shao TC, Kong A, Marafelia P, and Cunningham GR: Effects of finasteride on the rat ventral prostate. J Androl 14: 79-86, 1993.
17. Simard J, Luthy I, Guay J, Belanger A, and Labrie F: Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocr 44: 261-270, 1986.
18. Murphy WM, Soloway MS, and Barrows GH: Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68: 821-828, 1991.
19. Tetu B, Labrie F, Dupont A, and Monfette G: Histopathologic effect of combination therapy on normal prostate and prostatic adenocarcinoma, in Labrie F, Lee F, Dupont A (Eds.): Early Stage Prostate Cancer: Diagnosis and Choice of Therapy. Amsterdam, Excerpta Medica, 1989, 63-75.
20. Tetu B, Srigley JR, Boivin J-C, Dupont A, Monfette G, Pinault S, and Labrie F: Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma: a histopathologic and immunohistochemical study. Am J Surg Pathol 15: 111-120, 1991.
21. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Fair WR, and Reuter VE: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 18: 979-991, 1994.
22. Vailancourt L, Tetu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, and Labrie F: Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic adenocarcinoma. A randomized study. Am J Surg Pathol 20: 86-93, 1996.
23. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, and Sullivan LD: Effects of intermittent androgen suppression on androgen-dependent tumors. Cancer 71: 2782-2790, 1993.
24. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, and Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMO) prostate cancer. J Urol 154: 424-428, 1995.
25. 3 carcinoma treated by radical prostatectomy. Urology 44: 91-95, 1994.
26. Smith DM, and Murphy WM: Histologic changes in prostate carcinomas treated with Leoprolide (leutinizing hormone-releasing hormone effect): distinction from poor tumor differentiation. Cancer 73: 1472-1477, 1994.
27. Civantos F, Marcial MA, Banks ER, Ho CK, Speights VO, Drew PA, Murphy WM, and Soloway MS: Pathology of androgen deprivation therapy in prostate carcinoma: a comparative study of 173 patients. Cancer 75: 1634-1641, 1995.
28. Civantos F, and Soloway M: Finasteride (Proscar) effect in prostatic carcinoma (abst). Mod Pathol 9: 71A, 1996.
29. English HF, Kyprianou N, and Isaacs JT: Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15: 233-250, 1989.
30. English HF, Drago JR, and Santen RJ: Cellular response to androgen depletion and repletion in the rat ventral prostate: autoradiography and morphometric analysis. Prostate 7: 41-51, 1985.
31. Sandford NL, Searle JVV, and Kerr JF: Successive waves of apoptosis in the rat prostate after repeated withdrawal of testosterone stimulation. Pathology 16: 406-410, 1984.